Whitehawk Therapeutics stock soars after Tempus AI collaboration

Published 16/10/2025, 15:26
© Reuters.

Investing.com -- Whitehawk Therapeutics Inc (NASDAQ:WHWK) stock surged 67% following the announcement of a multi-year collaboration with Tempus AI, Inc. (NASDAQ:TEM) to advance biomarker-driven research for its oncology pipeline.

The partnership will leverage Tempus’ proprietary real-world dataset to support Whitehawk’s development of antibody drug conjugates (ADCs) for cancer treatment. Whitehawk will use Tempus’ de-identified multimodal database to refine clinical trial designs by identifying patient populations with demonstrated unmet needs.

The collaboration focuses on Whitehawk’s ADC portfolio, which includes three assets targeting clinically validated proteins (PTK7, MUC16 and SEZ6) expressed in cancer indications such as lung and gynecological cancers.

"A proactive approach to our biomarker strategy ensures our programs are guided by data-driven insights," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "By partnering with Tempus, our goal is to better understand the expression of our ADC protein targets to inform indication prioritization for our clinical development programs and better exploit the full potential of our pipeline."

Ryan Fukushima, Chief Operating Officer at Tempus, noted that the combination of Tempus’ multimodal data with Whitehawk’s ADC expertise creates "a powerful foundation to validate the potential of their portfolio in a promising class of targeted cancer therapeutics."

The companies will also work to establish concordance between RNA and IHC expression of targets, potentially enhancing patient identification capabilities for ADC therapies through more objective and scalable RNA testing methods.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.